Condition: Biliary Tract Cancer (BTC) · Sponsor: InnoPharmax Inc.
The object of this trial is to evaluate the efficacy of D07001-softgel capsules + capecitabine compared with placebo + capecitabine by overall survival (OS). Eligible patients with advanced biliary tract cancer (BTC) will be randomized (1:1:1) to receive either 60 mg D07001-softgel, 100 mg D07001-softgel, or placebo, combine with capecitabine. Treatment will be continued until disease progression, death, withdraw consent, or completing 12 treatment cycles , whichever occurs first.
This description comes directly from the study's public registry record.
Yuyuan Lin · 886-287977607 · yuan.lin@innopharmax.com
Always discuss trial participation with your own doctor first.
| Mount Sinai Medical Center | Miami Beach, Florida, United States | Recruiting |
| University Hospital Cleveland Medical Center | Cleveland, Ohio, United States | Recruiting |
| Kaohsiung Medical University Chung-Ho Memorial Hospital | Kaohsiung City, Taiwan | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06622057